NCT06809751

Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy

Evaluating Efficacy and Safety of Oral Melatonin in Acute Central Serous Chorioretinopathy (CSCR): a Double-blind Randomized Clinical Trial

• Status: Not Yet Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 48 (estimated)
• Sponsor: Mohsen Pourazizi · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if oral melatonin can enhance visual acuity and central macular thickness in central serous chorioretinopathy (CSCR) in adults. The main questions it aims to answer are: 1. How does melatonin affect central macula thickness in CSCR? 2. How does melatonin affect visual acuity in CSCR? Researchers will compare placebo (a look-like substance that contains no drug) to see if melatonin works to treat CSCR. Participants will: 1. Take melatonin or placebo twice a day for one month 2. Visit the clinic after finishing a course of treatment, and 1 and 3 months after that for visual acuity assessment and tests 3. Keep a diary of their symptoms

Conditions

• Central Serous Chorioretinopathy
• Melatonin
• Ocular Diseases
• Visual Acuity
• Macula Abnormality

Interventions

Type	Name	Description
DRUG	melatonin 3mg	In this group, participants will be randomly assigned to take 3 mg tablets of melatonin twice a day for 1 month.
DRUG	Placebo Drug	The placebo is also prepared in the form of tablets with similar packaging as melatonin by the pharmaceutical company. Participants will be randomly assigned to take placebo with the same frequency and duration as melatonin (twice a day for 1 month).

Timeline

• Start date: 2025-02-01
• Primary completion: 2025-05-01
• Completion: 2025-06-01
• First posted: 2025-02-05
• Last updated: 2025-02-05